Literature DB >> 2783873

Interaction of ibuprofen and warfarin on primary haemostasis.

S Schulman1, K Henriksson.   

Abstract

It has been stated that ibuprofen can be safely prescribed with concomitant warfarin. The effect of ibuprofen on primary haemostasis was investigated in 20 patients on warfarin for venous thromboembolism. Ibuprofen, 600 mg orally t.i.d., was added for 1 week. Bleeding time, prothrombin time, platelet count and urinalysis for haemoglobin were performed before and 90 minutes after the first dose and after 1 week. The bleeding time was significantly prolonged after 90 minutes (p less than 0.01) and after 1 week (p less than 0.05) and in four cases it was prolonged above the normal range. No clinical side-effects were observed apart from microscopic haematuria and haematoma. Thus, ibuprofen may cause clinical problems in some patients treated with warfarin, particularly in the elderly on complex drug regimens. It is advisable to check the bleeding time a few days after treatment with ibuprofen has been started in patients already on oral anticoagulation, and discontinue the former if the bleeding time is prolonged above the normal range.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783873     DOI: 10.1093/rheumatology/28.1.46

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  13 in total

Review 1.  Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous?

Authors:  M T Nurmohamed; W F Lems; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

2.  Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: a continuing matter of debate.

Authors:  M T Nurmohamed; B A Dijkmans; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

3.  Administration of tramadol or ibuprofen increases the INR level in patients on warfarin.

Authors:  Jacob Juel; Torben Brøchner Pedersen; Christian Sigvald Langfrits; Svend Eggert Jensen
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Lack of interaction between meloxicam and warfarin in healthy volunteers.

Authors:  D Türck; C A Su; G Heinzel; U Busch; E Bluhmki; J Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

6.  Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers.

Authors:  G Apseloff; K D Wilner; N Gerber
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

Review 7.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 8.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

9.  Adverse interaction between warfarin and indomethacin.

Authors:  R Day; D Quinn
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

Review 10.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.